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Abstract: OBJECTIVE
This randomised controlled trial tested a digitally-delivered whole-of-lifestyle program
for women previously treated for cancer. We investigated 1) any association between
self-reported physical activity (PA) and menopausal symptoms and 2) if the
intervention was associated with beneficial changes in PA and menopausal symptoms.
METHODS
Women were randomised to intervention (n=175) or control (n=176). The intervention
targeted lifestyle behaviours including physical activity. Self-reported PA (International
Physical Activity Questionnaire – Short Form) and menopausal symptom (Green
Climacteric Scale, GCS) data were collected at baseline, with measures repeated at 12
weeks (end of intervention) and 24 weeks (to assess sustainability). Generalised
estimating equation models assessed associations between physical activity and GCS
scores. Mixed-effects generalised equation models analysed changes within and
between groups in PA and GCS scores.
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
RESULTS
Total GCS score was 1.83 (95%CI: -3.55 to -0.11) and 2.72 (95%CI: -4.33 to -1.12)
lower in women with medium and high levels of PA, respectively, than in women with
low levels of PA. Total average GCS scores were 1.02 (-2.26 to 0.21) and 1.61 (-2.87
to -0.34) lower in those undertaking moderate or vigorous intensity PA, respectively.
Time spent walking, and performing moderate and vigorous PA were not different
between intervention and control. The average GCS decrease of 0.66 points (95%CI: -
1.29 to -0.03; p  time  =0.039) was not different between groups.
CONCLUSION
We established a stepwise association between moderate and vigorous PA and lower
menopausal symptoms. The intervention did not increase self-reported PA in women
treated for early stage breast, reproductive and blood cancers.
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OBJECTIVE: This randomised controlled trial tested a digitally-delivered whole-of-lifestyle program 
for women previously treated for cancer. We investigated 1) any association between self-reported 
physical activity (PA) and menopausal symptoms and 2) if the intervention was associated with 
beneficial changes in PA and menopausal symptoms.  
 
METHODS: Women were randomised to intervention (n=175) or control (n=176). The intervention 
targeted lifestyle behaviours including physical activity. Self-reported PA (International Physical 
Activity Questionnaire – Short Form) and menopausal symptom (Green Climacteric Scale, GCS) data 
were collected at baseline, with measures repeated at 12 weeks (end of intervention) and 24 weeks 
(to assess sustainability). Generalised estimating equation models assessed associations between 
physical activity and GCS scores. Mixed-effects generalised equation models analysed changes 
within and between groups in PA and GCS scores.  
 
RESULTS: Total GCS score was 1.83 (95%CI: -3.55 to -0.11) and 2.72 (95%CI: -4.33 to -1.12) lower in 
women with medium and high levels of PA, respectively, than in women with low levels of PA. Total 
average GCS scores were 1.02 (-2.26 to 0.21) and 1.61 (-2.87 to -0.34) lower in those undertaking 
moderate or vigorous intensity PA, respectively. Time spent walking, and performing moderate and 
vigorous PA were not different between intervention and control. The average GCS decrease of 0.66 
points (95%CI: -1.29 to -0.03; p time=0.039) was not different between groups. 
 
CONCLUSION: We established a stepwise association between moderate and vigorous PA and lower 
menopausal symptoms. The intervention did not increase self-reported PA in women treated for 
early stage breast, reproductive and blood cancers. 
 




Ovarian dysfunction is a common symptom in the large number of women treated for breast, 
reproductive and blood cancers. Breast cancer is the most common cancer in women worldwide, 
with over two million new cases in 2018 1. In Australia alone, a further 6,454 developed reproductive 
cancers2 and 5,286 were diagnosed with blood cancers3 such as leukaemia, lymphoma and multiple 
myeloma. Women often report that menopausal symptoms arising from treatment-induced ovarian 
failure as a distressing side effect that is ongoing long after they resume their usual work and social 
roles4. 
 
Menopausal symptoms arise when radiotherapy to the pelvic field, surgical removal or systemic 
chemotherapy damage the ovaries, initiating ovarian failure. In women who were pre- or peri-
menopausal prior to treatment, cancer therapies result in a sudden and sometimes irreversible 
menopause, the symptoms of which can be far more frequent and severe than in natural 
menopause4. In women who are post-menopausal at the time of treatment, extant vasomotor 
symptoms can be amplified by the endocrine therapies (e.g. tamoxifen and aromatase inhibitors) 
commonly prescribed for women with breast cancer5. 
 
Physical activity is an adjuvant non-hormone therapy that may influence menopausal symptoms and 
wellbeing in women treated for cancer6. Severe menopausal symptoms, including poor mental 
wellbeing, are associated with a sedentary lifestyle and low physical activity in healthy women who 
undergo natural menopause7,8. Recently we found that women treated for breast cancer who 
experience worse menopausal symptoms, including vasomotor symptoms, are less likely to 
engage in health-promoting behaviours9. Observational data10 also suggest that menopausal 
symptoms are less severe in people with cancer who state they undertake physical activity following 
treatment. Importantly, whilst higher levels of physical activity have been associated with reduced 
menopausal symptoms in heathy older women11, the potential influence of the components of 
physical activity (e.g. volume and intensity) on the relationship between menopausal symptoms and 
physical activity has not been investigated. 
 
Targeted interventions that improve health behaviours and increase physical activity could improve 
menopausal symptoms in women following cancer treatment. For example, in a pilot randomised 
controlled trial of women with a history of breast cancer treatment (N=53), our group showed that 
a lifestyle program incorporating a behavioural component aimed at enhancing health-related 
quality of life elicited clinically significant improvements in menopausal symptoms, including 
somatic and vasomotor symptoms and sexual function12.  
 
In this paper we report data from the Women’s Wellness after Cancer Program (WWACP) 
randomised controlled trial13. The WWACP trial tested a whole-of-lifestyle program for women 
previously treated for early stage breast, reproductive and blood cancers. The WWACP promoted 
evidence-based adoption of a range of lifestyle factors implicated in the development of chronic 
conditions after treatment in this group. Targeted lifestyle behaviours in the program included 
physical activity, nutrition, sleep hygiene, stress management, smoking cessation and alcohol 
minimisation. In women previously treated for early stage breast, blood and reproductive cancers, 
we aimed to investigate the association between self-reported physical activity levels and 
menopausal symptoms and if the WWACP intervention was associated with beneficial changes in 
physical activity and menopausal symptoms. We hypothesised that there would be a strong 
association between menopausal symptoms and physical activity in women following cancer 
treatment, and that greater volume and intensity of physical activity as encouraged in the WWACP 
would reduce menopausal symptoms experienced by women treated for cancer.  
 
Methods 
The dataset presented in this paper was collected as part of the multi-centre, single-blinded, 
randomised controlled 12-week WWACP13. A detailed description of the design, participant 
eligibility and outcome measures has previously been reported13.  
 
Participants and study design 
Three-hundred and fifty-one women treated for early stage breast, gynaecological or blood cancer 
within the previous 24 months were enrolled and randomly allocated to intervention (n=175) and 
control (n=176) groups. Women were recruited by clinicians from five hospitals (public and private); 
through the Wesley Hospital Choices Cancer Support Centre; and through newsletters, emails and 
websites of two consumer groups (the National Breast Cancer Foundations’ Register4, and the 
Breast Cancer Network of Australia). 
 
Intervention and control 
The WWACP intervention encouraged participants to systematically incorporate a healthy lifestyle 
(e.g. adherence to international dietary and physical activity guidelines14, sleep hygiene and stress 
modification) into daily life for 12 weeks. The intervention was delivered through a combination of 
a hard copy and digitally-delivered program book, internet interaction and three ‘face-to-face’ 
virtual consultations with an experienced cancer care nurse. The virtual consultations, which were 
undertaken via Skype, FaceTime or phone, were critical to the physical activity component. One 
consultation was undertaken at baseline to assess participants’ physical activity needs and tailor a 
physical activity program. A mid-intervention consultation was scheduled with participants in Week 
6 to review physical activity goals, capabilities and techniques, and modified physical activity as 
necessary. The third consultation took place at Week 12 (end of intervention), in which physical 
activity frequency was reviewed, along with participants’ goals for physical activity beyond the 
intervention period. Informal exchanges by phone and email with trained cancer care nurses also 
took place as the need arose.  
 
The physical activity components of the intervention were delivered through a hard copy book and 
digitally-delivered program based on the WCRF/AICR recommendations14 and were approached 
from a whole-of-lifestyle perspective. The physical activity component of the intervention was 
introduced in Week 1. In this introduction, the benefits of physical activity were explored along with 
the types of activity needed to enhance wellbeing and reduce sedentary practices that could 
compromise health after cancer treatment. Four days of Week 2 explored physical activity in more 
detail, in the context of participants’ busy lifestyles. Interactive content explored balance, core and 
pelvic floor issues; stretching and flexibility; strength training; and exercises without equipment. At 
the end of Week 2 and all subsequent weeks, participants were encouraged to reflect on what they 
had achieved with their physical activity to that point, and the new goals they would like to set for 
themselves in ensuing weeks of the program. From this point, participants were encouraged to 
engage in daily diarising of physical activity so that they could track whether this was consistent with 
recommended guidelines and their own personal goals. Week 4 was designated “Healthy Weight 
Week”, in which participants explored and practised physical activity and nutrition with healthy 
body composition in mind. Week 5 incorporated six days of physical activity content, introducing 
exercise with dumbbells, resistance bands and equipment available in fitness centres. Weeks 6 to 8 
incorporated content about the role of physical activity in conjunction with diet in preventing 
lifestyle disease after treatment such as diabetes, osteoporosis and cardiovascular disease. Week 9 
focused on the preventing cancer recurrence with a healthy lifestyle. Week 10 comprised a review 
of the participants’ physical activity practices to determine if any changes had been made and where 
further change might be needed. Weeks 11 and 12 examined motivation strategies to enhance self-
efficacy and sustain beneficial practices. Extra evidence updates relating to physical activity were 
posted on the study website as new evidence became available.  
 
The usual care group received no specific or individual advice, consistent with usual practice. 
General health information during their clinic visits about the management of all symptoms with 
physical activity might be provided if the clinician was aware of this. Control participants were 
offered a hard copy of the WWACP book upon completion of the trial (Week 24), with all content 
that was provided multi-modally offered to them in print form. 
 
Measures 
Data were collected at baseline, Week 12 (end of intervention) and Week 24 (to assess 
sustainability).  
 
Physical activity was measured with the short version of the International Physical Activity 
Questionnaire (IPAQ-SF)15. Comprising six items, the IPAQ-SF was used to determine the number of 
days and time spent in the previous week a) walking, b) at moderate-intensity, and c) at vigorous-
intensity physical activity, within four domains (occupational, household, leisure-time and 
transportation). Activities that lasted for at least 10 consecutive minutes were reported. 
 
Total minutes per week spent in each category was calculated by multiplying physical activity 
frequency and time.  Time per week spent in each category was multiplied by a metabolic equivalent 
task (MET; with one MET representing the energy cost at rest) value according to standard 
procedures (3.33 MET for walking; 4.0 MET for moderate activity, and 8.0 MET for vigorous activity). 
MET.minutes per week were summed, with participants’ activity categorized as low (0-599 
MET.minutes/week); medium (600–1199 MET.minutes/week); or high (1200+ MET.minutes per 
week). The proportion of participants reporting moderate and vigorous-intensity physical activity 
bouts of at least 10 minutes in duration was also determined. Women were deemed ‘active’ if they 
attained the recommended physical activity guidelines of 150 minutes of moderate-intensity or 75 
minutes of vigorous physical activity per week16. 
 
Menopausal symptoms were measured with the Greene Climacteric Scale (GCS)17. This 21-item 
scale assesses the common self-reported vasomotor, somatic and psychological symptoms (anxiety 
and depression) associated with menopause, as well as sexual function. The total GCS score is the 
sum of all 21 scores, with a maximum possible of 63. The higher the total score indicates severity of 
menopausal symptoms. The GCS has good psychometric properties in different cultural and health 
contexts when used with women experiencing menopause, and is recommended in this particular 
research context by Cancer Australia18. 
 
Statistical analysis 
Statistical analyses were undertaken with Stata 16 (StataCorp. 2019. Stata Statistical Software: 
Release 16. College Station, TX). Means, standard deviations and proportions provide the baseline 
characteristics of the sample. To compare baseline characteristics between the intervention and the 
control groups, Fisher’s exact test for categorical data and the student’s t-test for continuous data 
were used. To explore the two research questions, analyses were conducted in two steps. First, 
generalised estimating equation (GEE) models were used to assess associations between self-
reported physical activity and GCS scores and to account for the clustering of repeat measures 
within individuals. Random effect models were used to calculate the average difference with 
respective 95% confidence intervals in the GCS scores between participants with low, medium and 
high levels of physical activity. In addition, random effect models were also used to assess the 
association between reporting at least 10 minutes per week of moderate and vigorous-intensity 
physical activities with GCS scores. All analyses were adjusted for age, marital status, income, 
education, smoking, body mass index and menopausal status19. Given the exploratory aim of this 
study, regression coefficients and respective 95% confidence intervals were used to assess the 
statistical plausibility of the associations.  
 
Second, we investigated the effects of the intervention on physical activity levels and menopausal 
symptoms. For this, mixed-effects generalised equation models were used to analyse changes 
within and between groups in physical activity and GCS scores. The models included fixed terms for 
group and time, with a random intercept for each participant.  
 
Results 
At baseline, 278 (79%) participants reported their physical activities (140 intervention; 138 control). 
Most participants were treated for breast cancer (Table 1). At baseline, there were no differences 
between groups in age, education, BMI, smoking and menopausal status (p>0.1 for all comparisons). 
Further, ~80% of participants in the intervention and control groups were post-menopausal on 
diagnosis.  
 
Association between physical activity and menopausal symptoms  
The crude and adjusted associations between levels of physical activity and GCS scores are 
presented in Table 2. The average total GCS score at baseline was 16.0 (SD: 7.6). Overall, physical 
activity was inversely associated with total GCS scores in the crude and adjusted analyses. In the 
adjusted analyses, the total GCS score was -1.83 (95%CI: -3.55 to -0.11) and -2.72 (95%CI: -4.33 to -
1.12) lower in women with medium and high levels of physical activity, respectively, than in women 
with low levels of physical activity. Overall, physical activity was also associated with better specific 
domains of the GCS. With the exception of vasomotor symptoms, women with high levels of physical 
activity had lower scores for each menopausal domain than women who completed less than 600 
MET.minutes per week.  
Table 3 shows the association between menopausal symptoms and women reporting that that they 
undertook moderate or vigorous physical activity each week. Total average GCS scores were -1.02 
(-2.26 to 0.21) and -1.61 (-2.87 to -0.34) lower in those undertaking moderate or vigorous intensity 
physical activity, respectively. These observations in Table 2 and 3 remained when adjusted for 
potential cofounders. To confirm the robustness of these findings and account for time-invariant 
characteristics, fixed effect models were used. The changes in GCS scores that were associated with 
changes in physical activity categories observed in Table 2 and 3 remained following fixed effect 
analyses (see supplementary, Table 1). 
WWACP intervention outcomes 
Physical activity 
At baseline, ~75% of the cohort were deemed active based on current physical activity guidelines (≥ 
600 MET.minutes/week)20. Overall, most of the women reported that they were highly active, 
regardless of group and time point. Physical activity levels (low, medium and high) at each time 
point are presented in Figure 1. At baseline, the median MET.minutes per week was 1,336 (25th-
75th: 740-2,146) in the intervention group and 1,163 (25th-75th: 520-2,338) in the control group. 
Indeed, 58% of the women in the intervention and 48% of women in the control group reported 
more than 1200 MET.minutes per week of physical activity (Figure 1 and Table 4). These proportions 
increased to 67% in the intervention and 52% in the control group after 24 weeks (T2). Overall, there 
were no effects of group (OR 1.51; 95%CI: 0.55-4.12; p=0.426), time (OR: 1.16; 95%CI: 0.86-1.56; 
p=0.339) or interactions between group and time (OR: 1.18; 95%CI: 0.77-1.80; 0.447) when mixed-
effects ordered logistic regression models were used.  
 
Time spent undertaking each physical activity intensity (walking, moderate and vigorous) are 
presented in Figure 2. Time spent walking, and at moderate and vigorous intensity activity was not 
different between intervention and control, nor did time spent in each intensity significantly change 
at 12 and 24 weeks. Specifically, there was a small trend for an increase in time spent undertaking 
vigorous activity in both groups, however this was not significant (time-effect [β: 6.7 (95%CI: -5.3; 




Overall, there was an improvement in menopausal symptom scores over time in the intervention 
group, with an average decrease of 0.66 points (95%CI: -1.29 to -0.03; p time=0.039) in overall GCS 
score each 12 weeks over the study period (Table 4). The decrease in total GCS score was maintained 
in the intervention group at 24 weeks compared to control, however this was not significant (Table 
4). There were no significant interactions for the overall GCS score or menopausal sub-domains. 
Specifically, women in both groups reported an improvement in psychological symptoms at 12 and 








The first aim of this study was to establish whether there is an association between physical activity 
and menopausal symptoms in women treated with menopause-inducing cancer treatments. 
Overall, undertaking moderate and vigorous intensity physical activity was associated with fewer 
menopausal symptoms, albeit not vasomotor symptoms, than women who engaged in low intensity 
physical activity. Secondly, the WWACP intervention did not increase physical activity in women 
following cancer treatment.   
 
Similar to observations in healthy postmenopausal women7,8, we observed a clear association 
between physical activity and overall menopausal symptom severity in women after cancer 
treatment. There is a large body of research outlining the benefits of physical activity for mental 
health. It was recently shown that women who report higher levels of physical activity have fewer 
depressive symptoms associated with menopause 8. Our results support this. We previously showed 
that physical activity was a predictor of depressive symptoms in natural menopause, but not 
treatment-induced menopause after breast cancer9. A possible explanation for the clear association 
between physical activity and menopausal symptoms in this study is the addition of physical activity 
intensity, as well as volume, into the analysis. This study shows a dose-response association for 
vigorous and moderate physical activity and overall menopausal symptoms. Our findings also 
support the benefits of moderate and vigorous physical activity for reducing depressive symptoms 
in women following cancer treatment.  
 
We did not observe an association between higher physical activity levels and reduced vasomotor 
symptoms in women following cancer treatment. Instead, supervised and tailored exercise training 
that targets cardiovascular fitness could be of most benefit in women for alleviation of menopausal 
symptoms. In a pilot trial in healthy post-menopausal women, supervised and individually tailored 
exercise training which improved physiological determinants of vasomotor symptoms, including 
temperature regulation and cardiovascular fitness, alleviated menopausal symptoms21,22. As 
recently highlighted6, the type of physical activity could also be an important issue for investigating 
the association between physical activity and menopausal vasomotor symptoms23. For example, a 
systematic review and meta-analysis showed that yoga reduced menopausal and vasomotor 
symptoms23,24; whereas evidence for the benefits of aerobic exercise or resistance training on 
vasomotor symptoms remains inconclusive25. Future longitudinal trials should utilise objective 
measures of physical activity that enable analysis of the frequency, intensity, type and duration of 
physical activity undertaken. Only then will the modifiable factors associated with reduced 
menopausal symptoms in postmenopausal women, including those who have undergone cancer 
treatment, be understood.  
 
Physical activity also reduces the risk of other treatment-related chronic conditions, mortality and 
cancer recurrence in breast cancer survivors26. Recent data indicate that greater physical activity in 
women with breast cancer improves prognosis, especially for women who were insufficiently active 
at diagnosis27,28. Hence the second aim of this study was to investigate if the WWACP intervention 
increased physical activity levels and reduced menopausal symptoms in women following cancer 
treatment. In this sample, self-reported physical activity levels were mostly unchanged by the 
intervention. This is possibly because of self-selection bias in the sample, given that at baseline both 
groups were quite active already. In both the intervention and control groups, there was a small 
trend for a higher proportion of high physical activity (Figure 1) at Week 12 which was sustained at 
Week 24. While these changes were not statistically significant, intervention participants engaged 
in more intense physical activity than controls at all time-points. Overall, there was a small 
improvement in menopausal symptom scores in the intervention group at 12 weeks, with the 
decrease in total GCS score maintained in the intervention group after 24 weeks. Recently a positive 
relationship between cardiorespiratory fitness (V̇O2max) and menopausal symptoms was reported in 
healthy postmenopausal women29, however the effects in cancer survivors is unknown. Previous 
studies have also shown that exercise training that directly improves cardiorespiratory fitness 
reduces menopausal symptoms22,30. It is possible that future trials aimed at improving 
cardiorespiratory fitness by increasing moderate to vigorous physical activity could alleviate 
menopausal symptoms in women cancer survivors. 
 
While the perceived and actual benefits of physical activity after cancer treatment are well 
acknowledged31-33, enhancing and maintaining physical activity in this cohort is an ongoing 
challenge. Cancer patients generally express a preference for supervised exercise explicitly tailored 
to their needs like the WWACP, rather than home-based, more generic physical activity programs34. 
A meta-analyses also indicates that closely supervised exercise programs are superior to 
unsupervised programs in enabling exercise adherence and sustainability in cancer populations35. 
However, the less supervised format of the WWACP was developed in response to women’s explicit 
concerns about distance to exercise facilities, transport, parking costs and time, which they viewed 
as substantial obstacles to participation in closely-supervised exercise36,37. Although the WWACP 
was developed as a convenient and cost-effective solution to these concerns, the results indicate 
that more regular supervision of physical activity both during and beyond future programs is 
warranted. However, it is also seldom feasible for women to continue under the regular care of an 
exercise physiologist indefinitely without government-supported initiatives. Exercise self-efficacy is 
therefore critical to the safe and successful transition of women from supervised to unsupervised 
exercise, and key to the long-term maintenance of healthy lifestyle change following cancer 
treatment38. 
Limitations and strengths 
Self-reported physical activity as described by the IPAQ-SF has limitations. It has been shown that 
the instrument results in overestimations of physical activities across all intensities and 
underestimates physical inactivity in cancer survivors at baseline39. In this respect, in this cohort 
only 20-28% of women reported that they did not engage in moderate or high physical activity. This 
might indicate self-selection bias to the study in this cohort of women; however a previous lifestyle 
RCT found no self-election bias in those recruited through a registry compared with self-referal40. 
This could further result in biased estimates of effect sizes, which would underestimate the 
magnitude of the associations between physical activity and GCS scores. Although we adjusted our 
analyses for potential confounders of the associations between physical activity and GCS, residual 
confounding could partially explain the associations. However, we observed that the crude and 
adjusted analyses produced similar magnitude of associations, which suggests that the associations 
between physical activity and GCS are unlikely to be explained by confounding factors that were 
measured in our study. In the WWACP program we were not able to record adherence and 
engagement with specific components, including physical activity. Future iterations should closely 
monitor and record engagement and adherence to each aspect of the WWACP. 
 
Conclusions 
Climacteric symptoms are common and distressing in women previously treated for cancer, 
although services do not routinely offer post-treatment support. We established a clear stepwise 
association between moderate and vigorous physical activity levels and less symptoms of 
menopause in this group. Our 12-week WWACP intervention did not significantly increase physical 
activity levels compared to control. Future iterations of the WWACP will utilise closely supervised 
and prescribed exercise training to target menopausal symptoms and build exercise self-efficacy for 
longer-term maintenance in women following cancer treatment.   
 
Ethics and trial registration 
The protocol for this study is registered with the Australian and New Zealand Clinical Trials Registry 
(anzctr.org.au Trial ID: ACTRN12614000800628, July 28, 2014). This study was approved by 
Queensland University of Technology Human Research Ethics Committee (Approval No: 
1300000335) in July 2013. The study is also approved by the local ethics committees of all 
participating hospitals and health services (Peter MacCallum Cancer Centre, Metro South Hospital 
and Health Service, Royal Prince Alfred Hospital, St John of God Murdoch Hospital) and by the 
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Table and Figure Legend 
 
Table 1. Characteristics of intervention and control participants.  
Table 2. Linear regression model of climacteric symptoms in women with cancer reporting low, moderate 
and high physical activity domains  
Table 3. Linear regression model of climacteric symptoms in women with cancer answering yes/no to 
undertaking moderate and vigorous physical activity domains  
Table 4. Descriptive statistics for IPAQ-SF and GCS scores at baseline, 12 and 24 weeks between the 
intervention and control groups. IPAQ-SF data are displayed as median (IQR) and GCS data are displayed as 
mean (SD) unless otherwise stated. 
Figure 1. Physical activity levels over 24-weeks in the intervention and control groups. Low (<600 
MET.min/week); Moderate (600-1199 MET.minutes/week); High (1200+ MET.minutes/week). Group-effect 
[OR: 1.51 (95%CI: 0.55-4.13)]; time-effect [OR: 1.16 (95%CI: 0.86-1.56)]; time x group effect [OR: 1.18 (95%CI: 
0.77-1.80)]. 
 
Figure 2. Box plot of time (min per week) spent undertaking each physical activity intensity (walking, 
moderate and vigorous) over 24 weeks in the intervention and control groups. Walk: time x group effect [β: 
1.5 (95%CI: -31.8; 34.8); p=0.930]. Moderate: time x group effect [β: 10.0 (95%CI: -16.0; 36.0); p=0.450]. 
Vigorous: time x group effect [β: 4.4 (95%CI: -12.5; 21.2); p=0.610]. 
 





N=138 P-value  
n (%) n (%) 
Age (years)   0.132 
   < 40 13 (7.5) 4 (2.3)  
   40-50 49 (28.3) 50 (28.6)  
   50-60 66 (38.2) 77 (44.0)  
   60+ 45 (26.0) 44 (25.1)  
Marital status   0.845 
   Married or de facto 133 (77.3) 133 (76.4)  
   Separated/widowed/single 39 (22.7) 41 (23.6)  
Education   0.715 
   ≤ Year 10  13 (7.6) 18 (10.3)  
   Year 12 17 (9.9) 20 (11.5)  
   Technical / Diploma 42 (24.4) 37 (21.3)  
   University / Postgraduate 100 (58.1) 99 (56.9)  
Income   0.693 
  < $60,000 30 (17.5) 24 (13.8)  
   $60,000 - $120,000 72 (42.1) 81 (46.6)  
   > $120,000 62 (36.3) 60 (34.5)  
   Don’t know/missing 7 (4.1) 9 (5.2)  
Smoking status   0.197 
   Never 116 (66.7) 119 (68.0)  
   Past 54 (31.0) 46 (26.3)  
   Current 4 (2.3) 10 (5.7)  
Body Mass Index (kg/m2)   0.876 
   Normal  51 (35.6) 51 (38.1)  
   Overweight  52 (36.4) 45 (33.6)  
   Obese  40 (28.0) 38 (28.4)  
Menopausal Status   0.792 
   Premenopausal 13 (7.5) 10 (5.9)  
   Perimenopausal 24 (13.8) 22 (12.9)  




Table 2. Linear regression model of climacteric symptoms in women with cancer reporting low, 
moderate and high physical activity domains  
Outcome Random effect model 
 β crude (95% CI) β adjusted (95% CI) a 
GCS Total  
Low Ref Ref 
Moderate -1.15 (-2.58; 0.29) -1.83 (-3.55; -0.11) 
High -2.14 (-3.51; -0.77) -2.72 (-4.33; -1.12) 
Psychological  
Low Ref Ref 
Moderate -0.41 (-1.20; 0.39) -0.63 (-1.58; 0.32) 
High -1.23 (-2.00; -0.47) -1.31 (-2.22; -0.41) 
Somatic   
Low Ref Ref 
Moderate -0.70 (-1.24; -0.17) -0.80 (-1.42; -0.18) 
High -0.88 (-1.40; -0.36) -0.96 (-1.54; -0.37) 
Vasomotor   
Low Ref Ref 
Moderate 0.16 (-0.14; 0.46) 0.19 (-0.18; 0.55) 
High 0.14 (-0.15; 0.43) 0.16 (-0.19; 0.50) 
Sexual  
Low Ref Ref 
Moderate -0.06 (-0.24; 0.13) -0.13 (-0.35; 0.09) 
High -0.14 (-0.31; 0.04) -0.22 (-0.43; -0.02) 
Green Climacteric Scale (GCS). Low (<600 MET.min/week); moderate (600-1199 MET.minutes/week); 
High (1200+ MET.minutes/week). 










Table 3. Linear regression model of climacteric symptoms in women with cancer answering yes/no 
to undertaking moderate and vigorous physical activity domains  
Outcome Random effect model 
 β crude (95% CI) β adjusted (95% CI) a 
GCS Total  
Moderate -1.06 (-2.07; -0.06) -1.02 (-2.26; 0.21) 
Vigorous -1.33 (-2.38; -0.27) -1.61 (-2.87; -0.34) 
Psychological domain  
Moderate -0.82 (-1.38; -0.25) -0.83 (-1.52; -0.13) 
Vigorous -0.95 (-1.54; -0.36) -1.20 (-1.92; -0.48) 
Somatic domain  
Moderate -0.15 (-0.53; 0.24) -0.09 (-0.54; 0.36) 
Vigorous -0.25 (-0.66; 0.17) -0.10 (-0.58; 0.37) 
Vasomotor domain  
Moderate -0.12 (-0.34; 0.09) -0.05 (-0.32; 0.22) 




Moderate -0.11 (-0.24; 0.02) -0.14 (-0.30; 0.02) 
Vigorous -0.02 (-0.16; 0.11) -0.06 (-0.23; 0.10) 
Green Climacteric Scale (GCS).  
a Adjusted for age, marital status, education, income, smoking status, body mass index and 
menopausal status 
  
Table 4. Descriptive statistics for IPAQ-SF and GCS scores at baseline, 12 and 24 weeks between 
the intervention and control groups. IPAQ-SF data are displayed as median (IQR) and GCS data are 
displayed as mean (SD) unless otherwise stated. 
 




Time-point  Baseline Week 12 Week 24 Baseline Week 12 Week 24   
Physical activity 



















Green Climacteric Scale 
Psychological 
symptoms 
8.0 (4.8) 6.9 (4.4) 6.7 (4.5) 8.0 (4.9) 7.2 (4.9) 7.5 (5.1) 0.1 0.725 
Somatic 
symptoms 
4.1 (3.0) 3.5 (3.0) 3.6 (3.1) 4.7 (3.3) 4.1 (3.2) 4.5 (3.4) 0.2 0.234 
Vasomotor 
symptoms 
2.4 (1.7) 2.1 (1.7) 2.3 (1.7) 2.6 (2.0) 2.3 (1.8) 2.4 (1.9) 0.0 0.922 
Sexual 
function 
1.4 (1.0) 1.4 (1.0) 1.4 (1.0) 1.5 (1.0) 1.3 (1.0) 1.5 (1.0) 0.0 0.589 
Overall GCS 
score 
15.7 (7.3) 13.9 (7.6) 13.9 (7.5) 16.4 (8.0) 14.7 (8.0) 15.9 (9.1) 0.3 0.517 





Figure 1. Physical activity levels over 24-weeks in the intervention and control groups. Low 
(<600 MET.min/week); Moderate (600-1199 MET.minutes/week); High (1200+ 
MET.minutes/week). Group-effect [OR: 1.51 (95%CI: 0.55-4.13)]; time-effect [OR: 1.16 































Figure 2. Box plot of time (min per week) spent undertaking each physical activity intensity 
(walking, moderate and vigorous) over 24 weeks in the intervention and control groups. Walk: 
time x group effect [β: 1.5 (95%CI: -31.8; 34.8); p=0.930]. Moderate: time x group effect [β: 
10.0 (95%CI: -16.0; 36.0); p=0.450]. Vigorous: time x group effect [β: 4.4 (95%CI: -12.5; 21.2); 
p=0.610]. 
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